Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity
- 30 September 2013
- journal article
- clinical trial
- Published by Elsevier BV in Experimental Hematology
- Vol. 41 (9), 799-807.e4
- https://doi.org/10.1016/j.exphem.2013.04.012
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathwayOncogene, 2011
- Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemiaThe Journal of Experimental Medicine, 2010
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibitionMolecular Cancer Therapeutics, 2009
- Nuclear factor‐κB as a potential therapeutic target for the novel cytotoxic agent LC‐1 in acute myeloid leukaemiaBritish Journal of Haematology, 2008
- An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsBlood, 2007
- CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemiaProceedings of the National Academy of Sciences of the United States of America, 2007
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002
- Mechanism of action of the immunosuppressant rapamycinLife Sciences, 1995